Puretech Health PLC Company Profile (LON:PRTC)

About Puretech Health PLC (LON:PRTC)

Puretech Health PLC logoPureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: LON:PRTC
  • CUSIP: N/A
  • Web: puretechhealth.com/
Capitalization:
  • Market Cap: £317.9 million
  • Outstanding Shares: 236,358,000
Average Prices:
  • 50 Day Moving Avg: GBX 135.88
  • 200 Day Moving Avg: GBX 123.22
  • 52 Week Range: GBX 110 - GBX 166.10
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £4.85 million
  • Price / Sales: 65.55
  • Book Value: GBX 0.58 per share
  • Price / Book: 2.32
Profitability:
  • EBIDTA: ($94,050,000.00)
  • Net Margins: -10,126.32%
  • Return on Equity: -53.32%
  • Return on Assets: -47.28%
Misc:
  • Average Volume: 31,395 shs.
 

Frequently Asked Questions for Puretech Health PLC (LON:PRTC)

What is Puretech Health PLC's stock symbol?

Puretech Health PLC trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

Where is Puretech Health PLC's stock going? Where will Puretech Health PLC's stock price be in 2017?

5 brokerages have issued 1-year target prices for Puretech Health PLC's shares. Their predictions range from GBX 225 to GBX 259. On average, they expect Puretech Health PLC's share price to reach GBX 246.80 in the next twelve months. View Analyst Ratings for Puretech Health PLC.

Who are some of Puretech Health PLC's key competitors?

Who are Puretech Health PLC's key executives?

Puretech Health PLC's management team includes the folowing people:

  • Joichi Ito, Chairman of the Board
  • Daphne Zohar, Chief Executive Officer, Co-Founder, Director
  • Robert S. Langer Jr., Co-Founder, Non-Executive Director
  • Bennett M. Shapiro M.D., Co-Founder, Non-Executive Director
  • Bernat Olle Ph.D., Venture Partner
  • Michael F. MacLean, Chief Financial Officer, Executive Vice President
  • Stephen Muniz, Executive Vice President - Legal, Finance and Operations
  • Eric Elenko, Executive Vice President - Science & Technology
  • David Steinberg, Executive Vice President - Company Creation
  • Joseph B. Bolen Ph.D., Chief Scientific Officer

How do I buy Puretech Health PLC stock?

Shares of Puretech Health PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Puretech Health PLC's stock price today?

One share of Puretech Health PLC stock can currently be purchased for approximately GBX 134.50.


MarketBeat Community Rating for Puretech Health PLC (LON PRTC)
Community Ranking:  4.3 out of 5 (star star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Puretech Health PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Puretech Health PLC (LON:PRTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 246.80

Analysts' Ratings History for Puretech Health PLC (LON:PRTC)
Show:
DateFirmActionRatingPrice TargetDetails
8/30/2017Jefferies Group LLCReiterated RatingBuyGBX 225View Rating Details
8/30/2017Numis Securities LtdReiterated RatingBuyGBX 246View Rating Details
8/30/2017Liberum CapitalReiterated RatingBuyGBX 248View Rating Details
8/30/2017N+1 SingerReiterated RatingBuyView Rating Details
8/29/2017Peel HuntReiterated RatingBuyGBX 259View Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Puretech Health PLC (LON:PRTC)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Puretech Health PLC (LON:PRTC)
Current Year EPS Consensus Estimate: $-0.27 EPS

Dividends

Dividend History for Puretech Health PLC (LON:PRTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Puretech Health PLC (LON:PRTC)
Insider Trades by Quarter for Puretech Health PLC (LON:PRTC)
Insider Trades by Quarter for Puretech Health PLC (LON:PRTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/28/2016Scardino,Dame MarjorieInsiderBuy5,000GBX 135£6,750
10/26/2015Ito,JoichiInsiderBuy6,650GBX 149£9,908.50
10/9/2015Scardino,MarjorieInsiderBuy6,890GBX 126£8,681.40
9/28/2015Langer,RobertInsiderBuy7,200GBX 135£9,720
9/16/2015LaMattina,JohnInsiderBuy11,000GBX 146£16,060
9/10/2015LaMattina,JohnInsiderBuy5,492GBX 146£8,018.32
9/9/2015LaMattina,JohnInsiderBuy11,000GBX 147£16,170
9/4/2015LaMattina,JohnInsiderBuy11,000GBX 138£15,180
9/3/2015Scardino,MarjorieInsiderBuy10,000GBX 135£13,500
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Puretech Health PLC (LON:PRTC)
Latest Headlines for Puretech Health PLC (LON:PRTC)
Source:
DateHeadline
businesswire.com logoPureTech Health Exclusively Licenses Novel Milk-Derived Exosome Technology for Oral Administration of Biologics ... - Business Wire (press release)
www.businesswire.com - September 19 at 6:44 AM
finance.yahoo.com logoPureTech Health Exclusively Licenses Novel Milk-Derived Exosome Technology for Oral Administration of Biologics, Nucleic Acids, and Complex Small Molecules
finance.yahoo.com - September 19 at 6:44 AM
finance.yahoo.com logoPureTech Health Plc :PRTC-GB: Earnings Analysis: For the six months ended June 30, 2017 : September 6, 2017
finance.yahoo.com - September 7 at 7:53 AM
americanbankingnews.com logoLiberum Capital Reaffirms Buy Rating for Puretech Health PLC (PRTC)
www.americanbankingnews.com - August 31 at 12:32 AM
americanbankingnews.com logoPuretech Health PLC (PRTC) Stock Rating Reaffirmed by N+1 Singer
www.americanbankingnews.com - August 31 at 12:32 AM
americanbankingnews.com logoPuretech Health PLC (PRTC) Rating Reiterated by Numis Securities Ltd
www.americanbankingnews.com - August 30 at 10:34 PM
businesswire.com logoPureTech Health Exclusively Licenses Glyph Technology from Monash University to Harness Lymphatic Biology - Business Wire (press release)
www.businesswire.com - August 29 at 6:55 AM
finance.yahoo.com logoPureTech Health Exclusively Licenses Glyph Technology from Monash University to Harness Lymphatic Biology
finance.yahoo.com - August 29 at 6:55 AM
americanbankingnews.com logoPuretech Health PLC (PRTC) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 29 at 1:34 AM
finance.yahoo.com logoPureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Alivio Inflammation-Targeting Technology
finance.yahoo.com - July 13 at 8:14 AM
finance.yahoo.com logoGelesis Announces Last Patient Out in the Pivotal Gelesis100 Weight-Loss Study
finance.yahoo.com - July 12 at 7:09 AM
finance.yahoo.com logoFormer Cubist CEO, DreamWorks Interactive CEO, and Google Chief Game Designer Team-Up with Akili Interactive to Advance Digital Medicine Product Portfolio
finance.yahoo.com - June 28 at 9:00 AM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bullish Manner : PRTC-GB : June 26, 2017
finance.yahoo.com - June 26 at 8:05 AM
finance.yahoo.com logoPureTech Health Plc – Value Analysis (LONDON:PRTC) : June 15, 2017
finance.yahoo.com - June 16 at 9:04 AM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bullish Manner : PRTC-GB : June 14, 2017
finance.yahoo.com - June 14 at 8:45 AM
americanbankingnews.com logoPuretech Health PLC (PRTC) Receives Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - June 11 at 12:26 AM
finance.yahoo.com logoVedanta Biosciences Granted U.S. Patent Broadly Covering Methods of Treatment with Therapeutics Based on Bacterial Spore Fractions of Microbiota Obtained From Human Donors
finance.yahoo.com - May 30 at 9:44 AM
americanbankingnews.com logoPuretech Health PLC (PRTC) Rating Reiterated by N+1 Singer
www.americanbankingnews.com - May 28 at 5:14 PM
finance.yahoo.com logoPureTech Health to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 25 at 5:44 AM
finance.yahoo.com logoKaruna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
finance.yahoo.com - May 19 at 12:08 PM
finance.yahoo.com logoSync Project Announces New Investors and Accelerates Development of Personalized Music Health Platform
finance.yahoo.com - May 17 at 8:26 AM
finance.yahoo.com logoVedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia
finance.yahoo.com - May 16 at 9:45 AM
businesswire.com logoPureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of ... - Business Wire (press release)
www.businesswire.com - May 11 at 8:30 AM
finance.yahoo.com logoPureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections
finance.yahoo.com - May 9 at 11:00 AM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bearish Manner : PRTC-GB : May 5, 2017
finance.yahoo.com - May 5 at 8:29 AM
finance.yahoo.com logoPureTech Health Announces Licensing Agreement between Commense and the University of British Columbia for Microbiome-Derived Therapy
finance.yahoo.com - May 5 at 8:29 AM
finance.yahoo.com logoGelesis Announces €2.9 Million Award from Italian Ministry of Economic Development
finance.yahoo.com - May 3 at 7:40 PM
finance.yahoo.com logoPureTech Health Plc :PRTC-GB: Earnings Analysis: For the six months ended December 31, 2016 : April 26, 2017
finance.yahoo.com - April 26 at 10:59 PM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bearish Manner : PRTC-GB : April 24, 2017
finance.yahoo.com - April 24 at 2:31 PM
finance.yahoo.com logo[$$] Gormley's Take: With Risks, Medical Startup Investments Come to Masses
finance.yahoo.com - April 21 at 8:50 AM
finance.yahoo.com logoresTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer - Yahoo Finance
finance.yahoo.com - April 14 at 6:54 PM
finance.yahoo.com logoresTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer
finance.yahoo.com - April 13 at 9:39 AM
finance.yahoo.com logoPureTech Health Plc – Value Analysis (LONDON:PRTC) : April 12, 2017
finance.yahoo.com - April 12 at 1:44 PM
finance.yahoo.com logoPureTech Health Advances New Program Targeting Immunosuppressive Gamma Delta T Cells and Related Mechanisms
finance.yahoo.com - April 11 at 10:19 AM
finance.yahoo.com logoPureTech Health Plc breached its 50 day moving average in a Bullish Manner : PRTC-GB : April 11, 2017
finance.yahoo.com - April 11 at 10:19 AM
americanbankingnews.com logoLiberum Capital Reiterates "Buy" Rating for Puretech Health PLC (PRTC)
www.americanbankingnews.com - April 8 at 10:56 AM
finance.yahoo.com logoAkili Announces Results from Pilot Study Showing Treatment with Project EVO™ Improves Cognitive Control in Children with Sensory Processing Dysfunction and Attentional Deficits
finance.yahoo.com - April 7 at 12:02 PM
americanbankingnews.com logoJefferies Group LLC Reiterates "Buy" Rating for Puretech Health PLC (PRTC)
www.americanbankingnews.com - April 6 at 8:28 PM
americanbankingnews.com logoPuretech Health PLC (PRTC) Price Target Raised to GBX 246
www.americanbankingnews.com - April 4 at 1:18 PM
americanbankingnews.com logoPuretech Health PLC (PRTC) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 4 at 1:16 AM
americanbankingnews.com logoPuretech Health PLC's (PRTC) "Buy" Rating Reiterated at Numis Securities Ltd
www.americanbankingnews.com - March 30 at 5:43 AM
businesswire.com logoPureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 ... - Business Wire (press release)
www.businesswire.com - March 25 at 6:56 PM
americanbankingnews.com logoPuretech Health PLC (PRTC) Stock Rating Reaffirmed by Numis Securities Ltd
www.americanbankingnews.com - March 24 at 1:07 PM
finance.yahoo.com logoPureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 Programs
finance.yahoo.com - March 24 at 8:16 AM
americanbankingnews.com logoPuretech Health PLC's (PRTC) Buy Rating Reiterated at Peel Hunt
www.americanbankingnews.com - March 24 at 6:07 AM
uk.finance.yahoo.com logoPureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy
uk.finance.yahoo.com - March 2 at 8:30 AM
businesswire.com logoPureTech Health to Present at the Cowen and Company 37th Annual Health Care Conference - Business Wire (press release)
www.businesswire.com - February 25 at 1:39 AM
finance.yahoo.com logoPureTech Health to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 24 at 8:21 AM
uk.finance.yahoo.com logoPureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer
uk.finance.yahoo.com - February 23 at 8:49 AM
finance.yahoo.com logoVedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University …
finance.yahoo.com - February 17 at 8:06 PM

Social

Social activity is not available for this stock.

Chart

Puretech Health PLC (PRTC) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff